Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edwin DeJesus

Showing results (1-10 of 154) with videos related to

Pageof 16
Sort By:
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2004
New nucleoside/nucleotide backbone options: a review of recent studiesPeter J Ruane, Edwin DeJesus
Journal of Virus Eradication|December 17, 2020
Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world settingCharlotte-Paige Rolle, Vu Nguyen, Federico Hinestrosa, et al.
AIDS Research and Therapy|May 4, 2021
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIVCharlotte-Paige Rolle, Vu Nguyen, Federico Hinestrosa, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|June 27, 2023
Racial/ethnic disparities in HIV care outcomes among insured patients at a large urban sexual health clinicReanne Mathai, Federico Hinestrosa, Edwin DeJesus, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|December 2, 2020
Determinants of pre-exposure prophylaxis (PrEP) persistence in a high-risk population in Central FloridaJonathan Keyes, Eloisa Catherine Crouse, Edwin DeJesus, et al.
International Journal of STD & AIDS|July 24, 2020
Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatmentCharlotte-Paige Rolle, Omar Marquez, Vu Nguyen, et al.
Open Forum Infectious Diseases|October 17, 2024
Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD StudyCharlotte-Paige Rolle, Jamie Castano, Vu Nguyen, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|June 1, 2007
Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected PatientsEdwin DeJesus, Barry M Rodwick, Daniel Bowers, et al.
Medicine|September 24, 2021
Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIVCharlotte-Paige Rolle, Vu Nguyen, Kiran Patel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 9, 2024
Efficacy and Safety of 2 Fixed Doses of Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced HIV-Positive IndividualsEdwin DeJesus, William J Towner, Joseph C Gathe, et al.
Pageof 16

Showing results (1-10 of 154) with videos related to

Sort By:
Pageof 16
Journal of Acquired Immune Deficiency Syndromes (1999)|August 21, 2004
New nucleoside/nucleotide backbone options: a review of recent studiesPeter J Ruane, Edwin DeJesus
Journal of Virus Eradication|December 17, 2020
Clinical outcomes of HIV-1 infected patients switched from complex multi-tablet regimens to tenofovir alafenamide based single-tablet regimens plus a boosted protease inhibitor in a real-world settingCharlotte-Paige Rolle, Vu Nguyen, Federico Hinestrosa, et al.
AIDS Research and Therapy|May 4, 2021
Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIVCharlotte-Paige Rolle, Vu Nguyen, Federico Hinestrosa, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|June 27, 2023
Racial/ethnic disparities in HIV care outcomes among insured patients at a large urban sexual health clinicReanne Mathai, Federico Hinestrosa, Edwin DeJesus, et al.
Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|December 2, 2020
Determinants of pre-exposure prophylaxis (PrEP) persistence in a high-risk population in Central FloridaJonathan Keyes, Eloisa Catherine Crouse, Edwin DeJesus, et al.
International Journal of STD & AIDS|July 24, 2020
Clinical outcomes of once-daily darunavir in treatment-experienced patients with darunavir resistance-associated mutations through 48 weeks of treatmentCharlotte-Paige Rolle, Omar Marquez, Vu Nguyen, et al.
Open Forum Infectious Diseases|October 17, 2024
Efficacy, Safety, and Tolerability of Switching From Bictegravir/Emtricitabine/Tenofovir Alafenamide to Dolutegravir/Lamivudine Among Adults With Virologically Suppressed HIV: The DYAD StudyCharlotte-Paige Rolle, Jamie Castano, Vu Nguyen, et al.
Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002)|June 1, 2007
Use of Dronabinol Improves Appetite and Reverses Weight Loss in HIV/AIDS-Infected PatientsEdwin DeJesus, Barry M Rodwick, Daniel Bowers, et al.
Medicine|September 24, 2021
Real-world efficacy and safety of switching to bictegravir/emtricitabine/tenofovir alafenamide in older people living with HIVCharlotte-Paige Rolle, Vu Nguyen, Kiran Patel, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 9, 2024
Efficacy and Safety of 2 Fixed Doses of Ibalizumab Plus Optimized Background Regimen in Treatment-Experienced HIV-Positive IndividualsEdwin DeJesus, William J Towner, Joseph C Gathe, et al.
Pageof 16